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Summajy The aim of this study was to test the hypothesis of Goldie and Coldman that the use of
non-cross-resistant regimens of chemotherapy could lead to maximal anti-tumour effect. We compared
standard CMF (cyclophosphamide. methotrexate. fluorouracil) with alternating CMF EV (epirubicin, vincris-
tine) in the adjuvant therapy of early breast cancer. Stage II premenopausal node-positive or post-menopausal
node-positive oestrogen receptor-negative and stage III breast cancer patients were eligible for the study. From
January 1985 to December 1990. 220 patients were randomised (115 to CMF and 105 to CMF/EV). Toxicity
was mild: neurotoxicity. vomiting and hair loss were more frequent in the CMF/EV group, while permanent
amenorrhoea. diarrhoea, stomachache and minor infections occurred more often in the CMF arm. At a
follow-up of 48 months. 113 patients (51.4%) had had recurrence (62 on CMF and 51 on CMF/EV) and 54
(24.5%) had died (30 on CMF and 24 on CMF,EV). There was no significant difference in disease-free and
overall survival between the two arms. After adjusting for menopausal status and stage. the relative risk (RR)
of recurrence for CMF,EV patients was 0.93 (95% CL 0.64- 1.35). while the RR of death was 0.85 (95% CL
0.49-1.47). In conclusion, the Goldie-Coldman model of alternating therapy is not confirmed in this trial of
adjuvant therapy of early breast cancer, although in view of its design a difference of less than 20% in 3 year
disease-free survival could not be excluded.
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randomised clinical trial
Following the demonstration that adjuvant therapy,
especially CMF and tamoxifen, in patients<50 and .50
years respectively, significantly improves survival
(Bonadonna et al., 1976; Palshof et al., 1980; NATO, 1983;
Ludwig, 1984; Bianco et al., 1988), efforts have been aimed
at identifying patient subgroups that would benefit from the
two treatments and strategies that would improve the results
of treatments. A number of prospective randomised trials
were designed to address specific clinical questions, e.g.
optimal timing and scheduling of cytotoxic drugs and hor-
mones; optimal duration of tamoxifen administration; and
new strategies of drug administration to overcome tumour
resistance.
One of the proposed models involves alternating two non-
cross-resistant and equally effective drug combinations, ac-
cording to the Goldie-Coldman hypothesis (Goldie et al.,
1982). These investigators postulated that stable genetic alter-
ations arise in tumour cells and lead to the development of
cell phenotypes characterised by drug resistance. Thus, they
suggested that the early and concurrent administration of all
available anti-tumour agents would be the most effective
strategy. However, the overlapping toxic effects of this app-
roach may preclude its clinical application. The next best
alternative would be the use of non-cross resistant regimens
which, by attacking a population of tumour cells resistant to
one therapy but presumably not to the other therapy, would
lead to maximal anti-tumour effect and possibly cure more
patients.
At the time our study was designed, the evidence of
equiactivity and non-cross-resistance of CMF (cyclophos-
phamide, methotrexate, 5-fluorouracil) and AV (doxorubicin,
vincristine) regimens, in addition to promising results in
metastatic breast cancer (De Lena et al., 1975; Tormey et al.,
1982), provided the rationale to test the concept of the fixed
rotation of the two regimens in an adjuvant setting. Further-
more, the observation that 4-epi-doxorubicin, when used
alone or in combination with other cytotoxic agents, resulted
in equivalent objective response rates and overall median
survival in advanced breast cancer as doxorubicin parental
compound-containing regimens, but with lower cardiotoxic
potential (Jain et al., 1985), prompted us to replace AV with
EV (4-epi-doxorubicin, vincristine).
On 31 January 1985 the Cooperative Group of the Univer-
sity of Naples (GUN) began to recruit post-mastectomy stage
II premenopausal node-positive or post-menopausal node-
positive, presumably hormonoresistant, and stage III
operable breast cancer patients into a single-institution ran-
domised trial to evaluate whether adjuvant chemotherapy
employing an alternating CMF/EV regimen would improve
disease-free and overall survival as compared with the stan-
dard CMF regimen, and thus verify the Goldie-Coldman
model of alternating regimens. In this paper we report the 9
year results of the study.
Patients and methds
Patients
Patients with histologically confirmed. unilateral breast
cancer were eligible if they were: (a) stage II, premenopausal.
node-positive (N +) or post-menopausal, N +, oest-
rogen receptor negative (ER-); or (b) stage III. Other
requirements were: age .75; Karnofsky score 70; normal
blood counts (leucocyte 4 000 mm ', platelet
100 000 mmn3); and normal kidney [blood urea nitrogen
(BUN) and creatinine 1.25 x N] and liver [bilirubin,
glutamic-oxalacetic transaminase (GOT) and alkaline phos-
phatase (ALP) 1.25 x N] function. Electrocardiogram and
clinical examination were required to ascertain normal heart
rhythm and function.
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Primary treatment was either radical or modified radical
mastectomy or quadrantectomy for tumours<2cm followed
by high-voltage radiotherapy ofthe residual breast. Complete
axillary node dissection was required in all patients.
Patients were considered post-menopausal if they had had
their last menses at least 6 months before randomisation.
Oestrogen receptor assay was requested in post-menopausal
patients and performed by the biochemical assay described
elsewhere (De Placido et al., 1990).
Patients gave their informed consent to the study.
Study design and randomisation
Within 4 weeks of surgery, eligible patients were randomly
allocated to receive either six courses of CMF (control arm)
or the alternating CMF/EV regimen (study arm), consisting
of one course of CMF and one course of EV for a total of
six courses.
Randomisation was performed by permuted blocks within
strata; stratification criteria were: (a) menopausal status (pre/
post), (b) stage of diseas (I/II) and (c) within stage II
patients the number of metastatic nodes (1-3/>3), thus
creating six subgroups. Randomisation was carried out cent-
rally by telephone at the Oncology Department's Cancer
Trial Unit. The protocol design was fully approved by the
Ethics Committee of the University of Napls 'Federico II'.
From 31 January 1985 to 31 December 1990, 220 patients
entered the trial; 115 were assigned to standard CMF and
105 to alternating CMF/EV. The two arms were similar in
the distribution of major prognostic factor (Table I),
although a higher proportion of small tumours ( 2cm) was
observed in the CMF/EV arm.
Drug regimens
The standard CMF regimen was cyclophosphamide
l00mgm-2 orally on days 1-14, methotrexate 40mgm-2
and 5-fluorouracil 600mgm-2 intravenously on days 1 and 8
of a 28 day cycle that was repeated six times. The alternating
regimen consisted of the standard 28 day CMF cycle (same
dosage as the control arm) in cycles 1, 3 and 5 and a 21 day
EV course of 4-epi-doxorubicin 75 mgm-2 on day 1 and
vincristin 1.4mgm 2 on days 1 and 8 intravenously in the
even cycles, 2, 4 and 6; overall, six cycles were given, as in
the control arm.
Treatment toxicity was evaluated in accordance with WHO
criteria (Miller et al., 1981). Amenorrhoea was defined as
previously reported (Bianco et al., 1991).
In both arms chemotherapy was recycled at the planned
time if leucocyte and platelet counts were at least 4000 and
Tale I Characteistics ofpatients according to treatment arm
Variable CMF CMF/EV
No. (%) No. (%)
Age
<50 82 (71.3) 73 (69.5)
> 50 33 (28.7) 32 (30.5)
Menopausal status
Pre 85 (73.9) 74 (70.5)
Post 30 (26.1) 31 (29.5)
Stage
II 74 (64.3) 68 (64.8)
III 41 (35.7) 37 (35.2)
Tumour size (cn)
<,2 20 (19.4) 25 (26.0)
2.1-5 64 (62.1) 55 (57.3)
>5 19 (18.5) 16 (16.7)
No. ofmetastatic nodes
1-3 60 (52.2) 54 (51.4)
;¢4 55 (47.8) 51 (48.6)
Histological grade
GI +G2 24 (24.7) 23 (25.3)
G3 73 (75.3) 68 (74.7)
100 000 mm-3 respectively. Otherwise, a 1 week delay was
planned before starting the cycle. A 25% dose reduction in
case of grade I toxicity and a 50% dose reduction in the case
ofgrade II toxicity were planned on day 8 ofeach cycle. Day
8 was withdrawn in the case of grade III toxicity. In no case
was vncristine given at a dose of more than 2.0 mg. In the
case of diarrhoea and in the case of increasing liver enzymes,
the dose of 5-fluorouracil and methotrexate respectively were
recalculated.
Dose intensity was measured as mg m-2 body surface area
per week for each drug, regardless of the schedule used. In
both the CMF and CMF/EV arms the relative dose intensity
(RDI) was calulated for each patient as the ratio between
delivered and planned dose intensity (Hryniuk and Bush,
1984). For these calculations, it was assumed that each ofthe
single agents had approximately equivalent activity, and that
the CMF and EV regimens were of similar efficacy.
Studyparameters
Preoperatively patients were staged with bilateral mammog-
raphy, chest radiography, liver ultrasound, bone nuclear scan
and segmental bone radiography in the case of positive scan.
Clinical, haematologial and biochemical assessment of the
patients was done every 3 months for the first 2 years after
surgery, every 6 months up to the fifth year and every year
after the fifth. Chest radiography and liver ultrasound scan
were performed every 6 months up to the fifth year and once
per year from the sixth; mammography and bone nuclear
scan were performed every year for 5 years and then every 2
years. Computerised axial tomography and bone X-rays were
requested in the case of clinical or instrumental suspicion of
disease recurrence.
Statistical analysis
The present study was designed to detect a 20% difference
between the two treatment arms in 3 year disease-free sur-
vival (DFS) with type I error = 0.05, type II error = 0.20 and
expected 3 year DFS in the control arm = 60%. Under these
conditions, about 100 patients per arm were required.
The data analysed were those available at 31, May 1994;
the median follow-up was 48 months. Analyses were con-
ducted on the basis of intention to treat. The entry date was
the date of randomisation. DFS was defined as the time
elapsed from randomisation to the first relapse, i.e. one of
the following events: local rcurrenc, distant metastasis, con-
temporaneous local recur and distant metastasts, cont-
ralateral breast cancer or death without evidence of breast
cancer. Overall survival (OAS) was defined as the time from
randomisation to death. The Kaplan-Meier method (Kaplan
and Meier, 1958) was used to estimate DFS and OAS and
the Mantel-Haenszel test (Mantel, 1966) to estimate the
statistical signifi of the differences. The Cox propor-
tional hazard regression model (Cox, 1972) was used for
multivariate analysis where adjuvant treatment, menopausal
status and stage were entered as covanates. Stage, which was
defined as a three-modality variable (stage H with 1-3
positive nodes, stage II with more than three positive nodes
and stage HI), was coded into two dummy variables that
were included in the model. Multivariate analysis results were
expressed as relative risks (RR) with 95% confidence limits
(95% CL). All P-values were two-tailed. Statistics were elab-
orated with the BMDP package (BMDP Statistial Software,
Los Angeles, CA, USA).
Relts
Patient outcome
As of 31 May 1994, 113 patients (51.4%) experienced recur-
rence (62 in the CMF and 51 in the CMF/EV arm) and 54
(24.5%) of them died (30 in the CMF and 24 in the CMF/
EV arm). The sites of first recurrenc in the treatment arms
are lsted in Table H. Overall there was no significantmg S adjwaui chenapy fr breast cancer
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difference in DFS (Figure 1) and OAS (Figure 2) between the
two arms at univanate analysis. After adjusting by stage, and
nodal menopausal status, the RR of recurrence for CMF/EV
treated patients was 0.93 (95% CL 0.64-1.35), while the RR
of death was 0.85 (95% CL 0.49-1.47). The results of mul-
tivariate analysis are shown in Table III.
Side-effects
Patients generally experienced mild toxicity, which is reported
in Table IV. A higher incidence of vomiting and hair loss
was observed in the CMFiEV group, while permanent
amenorrhoea, diarrhoea, stomachache and minor infections
were more frequent in CMF-treated patients. Peripheral
neurotoxicity, i.e. constipation or paresthesies, occurred
exclusively in the CMF/EV arm, as expected from vincristine
toxicity.
Drug compliance
In patients who received CMF, the mean relative dose inten-
sity (RDI) for cyclophosphamide was 0.80, for methotrexate
0.81 and for 5-fluorouracil 0.83. with a mean value for the
combination of 0.81. In the alternating therapy arm, the
mean RDI for the individual drugs were 0.84 for cyclophos-
phamide, 0.89 for methotrexate, 0.89 for 5-fluorouracil, 0.79
for 4-epi-doxorubicin and 0.68 for vincristine, and the mean
RDI for the treatment regimen was 0.82.
Figure 3 shows the RDI for the two combination regimens
and for the single drugs in the two arms.
Table II Distribution ofsiteoffirstrelapseaccording to treatment arm
CMF CMF EEV
Site (n = 62) (n = 51)
Local 6 (9.7) 15 (29.4)
Distant 41 (66.1) 26 (51.0)
Local + distant 5 (8.1) 4 (7.8)
Second primary 6 (9.7) 2 (3.9)

















- CMF (115 patients)
-CMF/EV (105 patients)
1 2 3 4 5
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96 70 47 30 25
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Table m1 Multivariate analysis for disease free and overall survival
Disease-free
survival Overall survival
Variable RR 95% CL RR 95% CL
CMF EV vs CMF 0.93 0.64-1.35 0.85 0.49- 1.47
Stage 2 N 4 vs 2.27 1.39-3.72 4.54 1.97-10.44
stage 2 Nl-3
Stage 3 vs stage 2 NI -3 2.75 1.72-4.39 5.91 2.63- 13.29
Post- vs pre-menopausal 1.01 0.66-1.52 0.90 0.50- 1.65







------ CMF/EV (105 patients)
1 2 3 4 5
Years
109 94 64 40 32
100 91 64 40 26
survival curves.
Table IV Toxicity according to treatment arm
CMF CMFIEV
No.(%) No.(%) P-value
Leucocyte (grade 2-3) 38 (33.0) 35 (33.3) 0.%
Haemoglobin (grade 2 -3) 21 (18.3) 26 (24.7) 0.24
Platelet (grade 2-3) 0 (0.0) 4 (3.8) 0.11
Vomiting (grade 2-3) 53 (46.1) 61 (58.1) 0.07
Mucositis (grade 2) 7 (6.1) 6 (5.7) 0.91
Constipation (grade 1-2) 10 (8.7) 33 (31.4) <0.0001
Penrpheral neurotoxicity (grade 1-2) 0 (0.0) 43 (41.0) <0.0001
Hair loss (grade 2-3) 73 (63.5) % (91.4) <0.0001
Amenorrhoeaa 0.72
Transient 5 (5.9) 12 (16.2)
Permanent 58 (68.2) 41 (55.4)
Diarrhoea (grade 1-2) 22 (19.1) 8 (7.6) 0.01
Stomachache 20 (17.4) 13 (12.4) 0.30
Infections (grade 1) 6 (5.2) 0 (0.0) 0.05
AST/ALT (grade 1) 7 (6.1) 4 (3.8) 0.44
Cystitis (grade 1-2) 9 (7.8) 6 (5.7) 0.53
Conjunctivitis 13 (11.3) 8 (7.6) 0.35
'Only for premenopausal patients.
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FuGWe 3 Percentis of distribution of mean relative dose inten-
sities (see text for calculation) for combination regimens and for
single drugswithin each regimen. The horizontal ine of each box
plot, from the upper to the lower, represents 5th, 25th, 50th, 75th
and 95th percentiles of the distribution (C = cydophosphamide,
M = methotrexate, F = 5-fluorouraci, E = epi-doxorubicin,
V = vincristine).
Dsensdo
This study was designed to test in a clinical setting the
Goldie and Coldman hypothesis that drug resistance arise
before and durig treatment and suggests the use of as many
effective drugs as possible, as early as possible, in order to
overcome the expected heterogeneity in resistance
mechanisms and to maximise the probability of cure. When
the overlapping toxicity prevents the simultaneous administ-
ration of all active agents, Goldie and Coldman (Goldie et
al., 1982) recommend that two non-cross-resistant egimens
(regimen 'A' and regimen 'B') be used in a rapidly alternating
fashion (i.e ABABAB) to produce optimal results. However,
this strategy assumes a large degree of symmetry both (i)
between the two treatment sets with respect to log kills on
sensitive cells and (ii) among the cell clones with respect to
mutation rates to resistance or allowable recovery times
between treatment cycles.
The idea of alternating CMF and EV as a means of
evaluatng the Goldie and Coldman model in breast cancer
was supported by the results of two clinical trials in advanced
diseas that strongly suggested that these regimens are
equivalntly active and cinially non-cross-resstant (De
Lena et al., 1975; Tormey et al., 1982).
The results of this randomised study which compares six-
cycle CMF with alternating CMF and EV schedules for a
total of six cycles, failed to show a significant difference in
survival between the two treatment sets. This negative result
may be due to various factors.
Firstly, the survival advantage induced by CMF/EV could
be very small and, thus, below the power of detection of the
study.
Secondly, most of the assumptions forming the base of the
Goldie-Coldman hypothesis are not met in human cancer,
particulaly in breast cancer. Norton and Simon (Norton and
Simon, 1986; Norton, 1988), reconsidering cell growth
kinetics, suggested that a single tumour is characterised by
many subclones, each of them growing along a differing
Gompertzian curve. Furthermore, these subclones could be
not symmetrical in their resistance or in their rate of muta-
tion toward resistance. This line of thinking seems to reflect
more accurately tumour heterogeneity and the clinical situa-
tion.
Thirdly, breast cancer simply may not be a good model for
the Goldie-Coldman hypothesis, because of its kinetics char-
acteristics (slow growing tumour) and its intrinsic
mechanisms of resistance (high expression of the p170
glycoprotein). In a series of randomisedtrials on advanced
breast cancer (Kennealeyet al., 1978; Nemotoet al., 1982;
Vogel et al., 1984), which varied in size from about 50 to
more than 300 patients, the discouraging results were re-
markably similar. alternation ofregimens did not improve
the response rates or survival pattern of patients with respect
to those treated with a single combination regimen. One of
the most interesting of these studies was that performed by
the Eastern Cooperative Oncology Group (ECOG). Patients
were randomised to receive either CMF or CMF alternating
with AV. Interestingly, while the response rates for the
rotating combination were not higher than that for the single
regimen, duration of survival was significantly prolonged.
However, when CMFP (CMF plus prednisone) was com-
pared with CMFP alternating with AV, the two treatment
programmes were equivalent in response rates and duration
of survival, probably because CMFP is better than CMF
(Tormey et al., 1983).
In the adjuvant setting, two other studies have been con-
ducted in which the use of alternating regimens was inves-
tigated to verify the mathematical model of Goldie and
Coldman. A phase III trial by the ECOG randomised 533
premenopausalN+ patients to receive either CMFPT (CMF
plus prednisone and tamoxifen) or the same regimen plus
halotestin alternating monthly with VATHT (vinblastine,
doxorubicin, thiotepa, halotestin, tamoxifen). At a 5.1 year
follow-up, the time to relapse was superior for thealternating
rgimen, while there was no statistical difference between the
two treatmentregimens in terms ofoverall survival (Tormey
et al., 1992). Another prospective randomised trial examined
the effect of CMF vs alternating CMF/AV in stageII. N+
patients. At 4 years there was no difference in outcome
between the treatment arms (Chaitchiket al., 1989).
The Goldie and Coldman alternating strategy has also
been clinically tested in Hodgkins's disease and in small-cell
lung cancer (SCLC). These malignancies seem to be useful
models, being among the few cancers for which many
effective drug treatments are available. Although an early
trial in Hodgkn's disease suggested a significant prolonga-
tion in DFS and OS (Bonadonna et al., 1986), subsequent
studies did not find that alternating regimens provided
significantly better results than did adequately used four-drug
combinations (Longo et al., 1991; Canellos et al., 1992).
Recently, atleast five large randomised trials have tested the
use ofalternating non-crossresistant chemotherapy in SCLC.
Of the four studies conducted in patients with extensive-stage
disease (Evans et al., 1987; Fukuoka et al., 1991; Wolfet al.,
1991; Rothet al., 1992), only one trial found a significant
improvement of median survival in favour of the alternating
schedule, but the magnitude of benefit was modest (Evans et
al., 1987). Similarly, for patients with limited-stage disease,
the median survival was significantly better with the alter-
nating regimen m one (Fukuoka et al., 1991) of the three
reported studies (Goodman et al., 1990; Fukuoka et al.,
1991; Wolf et al., 1991). However, this positive result must be
interpreted with caution, given the small number oflimited-
stage patients included in the trial.
In conclusion, in breast cancer, as well as in other malig-
nancies, the data available do not support the hypothesis of a
significant advantage for the use of rapidly alternating
schedules as compared with a single active regimen. In addi-
tion, toxicity is often more pronounced with alternating
regimens.
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